CompoAtlas

Total Rush 2.0 Cola

Food supplement declared in France, declaration No 2024-2-1153, decision dated 19 February 2024

Total Rush 2.0 Cola is a food supplement declared in France. Status: declared in France, may be marketed. None of the rules we check flags an issue with its declared composition; vitamin and mineral doses are not published by Compl'Alim and are therefore not checked.

Brand
not provided
Food business operator placing the product on the market
WEIDER NUTRITION SL
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Powder
Daily dose
1 portion par jour; de préférence avant l'entraîne
Directions for use
Mélanger 25 g de poudre (1cuillère) avec 300 ml d'eau.

Declaration 306805, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Amaranthus hypochondriacus L.FeuilleExtrait fluide aqueux300 mg

Other active ingredients

NamePer day
L-citrulline malatenot declared
Chlorhydrate de L-argininenot declared
Créatine monohydratenot declared
Bêta-alaninenot declared
N-acétyl L-tyrosinenot declared
Taurinenot declared
Glycinenot declared
L-alanyl-L-glutaminenot declared
Caféinenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
Carbonate de calciumCalcium2,500 mg800 mg
NicotinamideNicotinamide (vitamine B3)900 mg54 mg
CyanocobalamineVitamine B12pas d'effet indésirable définidose annulled by the French Council of State in 2011
Chlorhydrate de pyridoxineVitamine B612 mg2 mg
Acide L-ascorbiqueVitamine Cpas de limite (données insuffisantes)180 mg
CholécalciférolVitamine D100 µg (4,000 UI)5 µg (200 UI)
Oxyde de zincZinc25 mg15 mg

Additives

E330, E551, E340, E950, E952, E954, E955, E150c

Other ingredients

maltodextrine, huile de tournesol

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Les compléments alimentaires ne doivent pas être utilisés en remplacement d’une alimentation variée et équilibrée et à un mode de vie sain. Ne pas dépasser la dose journalière conseillée. Maintenir hors de la portée des enfants.Teneur élevée en caféine (200 mg par portion). Ne convient pas aux enfants, aux femmes enceintes ou allaitantes, aux personnes souffrant d'hypertension et de troubles cardiovasculaires. Ce produit est destiné uniquement aux adultes pratiquant une activité physique intense.

Regulatory points

None of the rules we check applies to the declared ingredients.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Créatine monohydrate
    Read the warning, when it applies and the studies cited

    Creatine Monohydrate

    Route of administration: Oral

    Cautions and warnings

    When using this product you may gain weight (Volek and Rawson 2004; Bemben et al. 2001; Mihic et al. 2000).

    Sources cited by Health Canada (3)
    • Bemben MG, Bemben DA, Loftiss DD, Knehans AW. 2001. Creatine supplementation during resistance training in college football athletes. Medicine & Science in Sports & Exercise 33(10):1667-1673.
    • Mihic S, MacDonald JR, McKenzie S, Tarnopolsky MA. 2000. Acute creatine loading increases fat-free mass, but does not affect blood pressure, plasma creatinine, or CK activity in men and women. Medicine & Science in Sports and Exercise 32(2):291-296.
    • Volek JS, Rawson ES. 2004. Scientific basis and practical aspects of creatine supplementation for athletes. Nutrition 20(7-8):609-614.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder (Pline and Smith 2005; Pritchard and Kalra 1998).

    Sources cited by Health Canada (2)
    • Pline KA, Smith CL. 2005. The effect of creatine intake on renal function. The Annals of Pharmacotherapy 39(6):1093-1096.
    • Pritchard NR, Kalra PA. 1998. Renal dysfunction accompanying oral creatine supplements. The Lancet 351(9111):1252-1253.

    Health Canada monograph dated 28 June 2024

  • Taurine
    Read the warning, when it applies and the studies cited

    TAURINE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Lopez Ramon et al. 2007; Seghieri et al. 2007).

    Sources cited by Health Canada (2)
    • López Ramón Y Cajal C, Ocampo Martínez R, Couceiro Naveira E, Martínez M. Amino acids in amniotic fluid in the 15th-16th weeks of gestation and preterm labor. The Journal of Maternal-Fetal & Neonatal Medicine: the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2007;20(3):225-231.
    • Seghieri G, Tesi F, Bianchi L, Loizzo A, Saccomanni G, Ghirlanda G, Anichini R, Franconi F. Taurine in women with a history of gestational diabetes. Diabetes Research and Clinical Practice 2007;76(2):187-192. PubMed

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 30 January 2026

  • Caféine
    Read the warning, when it applies and the studies cited

    CAFFEINE

    Route of administration: Oral (Higdon and Frei 2006)

    Cautions and warnings

    Applies to products providing 100 mg to 400 mg caffeine, per day1.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    Sources cited by Health Canada (7)
    • Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
    • Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Randomised trial
    • Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
    • Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Review article
    • Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Clinical trial
    • Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Meta-analysis
    • Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Meta-analysis

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Applies to products providing more than 300 mg caffeine, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant, breastfeeding, or attempting to conceive (Nawrot et al. 2003).

    Sources cited by Health Canada (1)
    • Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Additives and Contaminants 2003;20(1):1-30. PubMed Review article

    Applies to products providing 400 mg or more caffeine, per day.

    When using this product avoid taking other health products, foods or beverages that contain caffeine and/or increase blood pressure (FDA 2023; Bui et al. 2006; Bouchard et al. 2005; Haller et al. 2005; NIH 2004; Berardi et al. 2002; Vahedi et al. 2000; Zimmerman 1992).

    Sources cited by Health Canada (8)
    • Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
    • Bouchard NC, Howland MA, Greller HA, Hoffman RS, Nelson LS. Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clinic Proceeding 2005;80(4):541-545. PubMed Case report
    • Bui LT, Nguyen DT, Ambrose PJ. Blood pressure and heart rate effects following a single dose of bitter orange. The Annals of Pharmacotherapy 2006;40(1):53-57. PubMed Randomised trial
    • FDA 2023: Food and Drug Administration. Title 21 Chapter 1 Part 340. Stimulant drug products for over-the-counter human use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services; 2023. [Accessed 2023 Aug 28]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=340&showFR=1
    • Haller CA, Benowitz NL, Jacob P. Hemodynamic effects of ephedra-free weight-loss supplements in humans. The American Journal of Medicine 2005;118(9):998-1003. PubMed Randomised trial
    • NIH 2004: National Institutes of Health. Office of Dietary Supplements. Fact sheets. Ephedra and ephedrine alkaloids for weight loss and athletic performance; 2004. [Accessed 2023 August 28]. Available from: https://ods.od.nih.gov/factsheets/ephedraandephedrine-HealthProfessional/.
    • Vahedi K, Domingo V, Amarenco P, Bousser MG. Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building. Journal of Neurology, Neurosurgery and Psychiatry 2000;68(1):112-113. PubMed Case report
    • Zimmerman DR. Zimmerman's Complete Guide to Nonprescription Drugs, 2nd edition. Detroit (MI): Gale Research Inc.; 1992.

    Contraindications

    Applies to products providing more than 400 mg caffeine per day.

    Do not use if you have high blood pressure or glaucoma (Cornelis and El-Sohemy 2007, Chandrasekaran et al. 2005, Noordzij et al. 2005, Avisar et al. 2002, Arya et al. 2000, Jee et al. 1999, Creighton and Stanton 1990).

    Sources cited by Health Canada (7)
    • Arya LA, Myers DL, Jackson ND. Dietary caffeine intake and the risk for detrusor instability: a case-control study. Obstetrics and Gynecology 2000;96(1):85-89. PubMed
    • Avisar R, Avisar E, Weinberger D. Effect of coffee consumption on intraocular pressure. The Annals of Pharmacotherapy 2002;36(6):992-995. PubMed Randomised trial
    • Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. Journal of Glaucoma 2005;14(6):504-507. PubMed
    • Cornelis MC, El-Sohemy A. Coffee, caffeine, and coronary heart disease. Current Opinion in Lipidology 2007;18(1):13-19. PubMed Review article
    • Creighton SM, Stanton SL. Caffeine: does it affect your bladder? British Journal of Urology 1990;66(6):613-614. PubMed Clinical trial
    • Jee SH, He J, Whelton PK, Suh II, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33(2):647-652. PubMed Meta-analysis
    • Noordzij M, Uiterwaal CS, Arends LR, Kok FJ, Grobbee DE, Geleijnse JM. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. Journal of Hypertension 2005;23(5):921-928. PubMed Meta-analysis

    Known adverse reactions

    Condition of application: All products.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if hypersensitivity/allergy occurs (Infante et al. 2003; Hinrichs et al. 2002).

    Sources cited by Health Canada (2)
    • Hinrichs R, Hunzelmann N, Ritzkowsky A, Zollner TM, Krieg T, Scharffetter-Kochanek K. Caffeine hypersensitivity. Allergy 2002;57(9):859-860. PubMed Case report
    • Infante S, Baeza ML, Calvo M, De Barrio M, Rubio M, Herrero T. Anaphylaxis due to caffeine. Allergy 2003;58(7):681-682. PubMed Case report

    Applies to products providing 200 mg or more caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms such as chest pain and irregular heartbeat occur (Higgins and Babu 2013).

    Sources cited by Health Canada (1)
    • Higgins JP, Babu KM, Caffeine reduces myocardial blood flow during exercise. The American Journal of Medicine 2013;126(8):730-e 1-8.

    Applies to products providing more than 400 mg caffeine, per day.

    Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if nervousness, anxiety, insomnia, tremor and/or headache occur (IOM 2001, Zhang 2001, Sawynok 1995).

    Sources cited by Health Canada (3)
    • IOM 2001: Institute of Medicine. Committee on Military Nutrition Research, Food and Nutrition Board, Institute of Medicine. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations. Washington (DC): National Academy Press; 2001 [Accessed 2023 Aug 28]. Available from: http://books.nap.edu/openbook.php?isbn=0309082587.
    • Sawynok J. Pharmacological rationale for the clinical use of caffeine. Drugs 1995;49(1):37-50. PubMed Review article
    • Zhang WY. A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Safety 2001;24(15):1127-1142. PubMed Review article

    Condition of application: All products except those making a diuretic claim1.

    When using this product diuretic effect may occur.

    1Note: This statement is also required at subtherapeutic quantities for products providing 40 mg or more caffeine per day from all sources for Class II and III applications.

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2024. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line